 BeyondSpring Inc. the Company or BeyondSpring BYSI, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the launch of an underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15 of the ordinary shares being offered. The Company also intends to sell additional ordinary shares to entities affiliated with Decheng Capital in a separate private placement transaction. 